Val­sar­tan CAS 137862-53-4

Iden­ti­fi­ca­tion Prop­er­ties Safe­ty Data Spec­i­fi­ca­tions & Oth­er Information Links

Iden­ti­fi­ca­tion

CAS Number

137862-53-4

Name

Val­sar­tan

Syn­onyms

(2S)-3-Methyl-2-(pentanoyl{[2′-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}amino)butanoic acid (2S)-3-Methyl-2-(pentanoyl{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)butanoic acid (2S)-3-Methyl-2-(pentanoyl{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)butansäure [Ger­man] (S)-N-(1-Carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]amine 137862-53-4 [RN] 7016 80M03YXJ7I Acide (2S)-3-méthyl-2-(pentanoyl{[2′-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl}amino)butanoïque [French] L-Valine, N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- [ACD/​Index Name] N-(1-Oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine N-Pentanoyl-N-{[2′-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-L-valin [Ger­man] [ACD/IUPAC Name] N-Pentanoyl-N-{[2′-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-L-valine [ACD/IUPAC Name] N-Pentanoyl-N-{[2′-(1H-tétrazol-5-yl)-4-biphénylyl]méthyl}-L-valine [French] [ACD/IUPAC Name] N-Pentanoyl-N-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valin N-Pentanoyl-N-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine N-Pentanoyl-N-{[2′-(2H-tetrazol-5-yl)-4-biphenylyl]methyl}valin [Ger­man] [ACD/IUPAC Name] N-Pentanoyl-N-{[2′-(2H-tetrazol-5-yl)-4-biphenylyl]methyl}valine [ACD/IUPAC Name] N-Pentanoyl-N-{[2′-(2H-tétrazol-5-yl)-4-biphénylyl]méthyl}valine [French] [ACD/IUPAC Name] N-Pentanoyl-N-{[2′-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine Valine, N-(1-oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- [ACD/​Index Name] Val­sar­tan [INN] [JAN] [USAN] [Wiki] (2S)-3-Methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid (2S)-3-Methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid (2S)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid (2S)-3-Methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid (S)-2-(N-((2′-(1H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid (S)-2-(N-((2`-(1H-Tetrazol-5-yl)-[1,1`-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid (S)-3-Methyl-2-{pentanoyl-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid (S)-3-Methyl-2-{pentanoyl-[2′-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[(2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]amine (S)-N-valeryl-N-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine (S)-N-Valeryl-N-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine ; Dio­van ; N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine ; N-pentanoyl-N-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine [137862-53-4] 3-Methyl-2-{((S)-pentanoyl)-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid 7754038 [Beil­stein] BR-58790 C24H29N5O3 CGP 48933 | CGP 48933;Diovan;Tareg ;CGP48933 ;CGP-48933 CGP48933 CGP-48933 CGP-48933|Dio­van® Dio­van [Wiki] DIO­VAN HCT Dio­van® EXFORGE Kal­press L-Valine, N-(1-oxopentyl)-N-((2′-(1H-tetrazol-5-yl)(1,1′-biphenyl)-4-yl)methyl)- L-Valine,N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-3-yl]methyl]- (9CI) L-Val­sar­­tan MFCD00865840 [MDL num­ber] Miten N-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine N-(1-oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine N-(1-Oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine N-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine Nisis N-pentanoyl-N-{[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl}-L-valine n-valeryl-n-[2-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-l-valine Phar­­makon1600-01505209 Provas Tareg UNII :80M03YXJ7I UNII-80M03YXJ7I Vals Val­sar­tan (Dio­van) val­sar­tan, ??? val­sar­tan, [3h]- val­sa­tarn Val­tan YV9455000 YV9455000 [RTECS]

Mol­e­c­u­lar Structure

SMILES

CCC­CC(=O)N(Cc1ccc(cc1)c2ccccc2c3[nH]nnn3)[C@@H](C(C)C)C(=O)O

Std­InChI

InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

Std­InChIKey

ACW­BQPMHZXGDFX-QFIPXVFZSA-N

Mol­e­c­u­lar Formula

C24H29N5O3

Mol­e­c­u­lar Weight

435.52

MDL Number

MFCD00865840

Safe­ty Data

Haz­ard Statements

H413

RIDADR

NONH for all modes of trans­port

WGK Germany

3 

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Val­sar­tan CAS 137862-53-4

Stan­dard

EP, USP

GMP

CFDA

Basic Patent Situation

US expiry date	20120321
EU expiry date	20110212 (20110512)
JP expiry date	20160219

Pack­age

Accord­ing to cus­tomer require­ments to pack­ag­ing

Stor­age

Under the room tem­per­a­ture and away from light

Appli­ca­tion

Used as the Angiotensin II Recep­tor Antag­o­nist

Links

This prod­uct is devel­oped by our R&D com­pa­ny Wat­son­noke Sci­en­tif­ic Ltd(http://​www​.wat​son​noke​.com/), and here is the cor­re­spond­ing linkhttp://​www​.wat​son​noke​.com/​v​a​l​s​a​r​t​a​n​-​c​a​s​-​1​3​7​8​6​2​-​5​3​-4/

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you short­ly (Please change screen to hor­i­zon­tal for com­plete brows­ing if you are check­ing Wat­son on your mobile phone).